N@N

Skystar Bio-Pharmaceutical Company: Skystar Bio-Pharmaceutical Retains The Piacente Group as Strategic Investor Relations Consu

_{//science-technology.news-articles.net/content/2 .. group-as-strategic-investor-relations-consu.html}
^{Published in Science and Technology on Thursday, July 9th 2009 at 5:44 GMT, Last Modified on 2009-07-09 05:45:00 by Market Wire}  

XI'AN, CHINA--(Marketwire - July 9, 2009) - Skystar Bio-Pharmaceutical Company (NASDAQ: [ SKBI ]) ("Skystar" or the "Company"), a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that it has retained The Piacente Group, Inc. ("TPG"), a full service investor relations consulting firm based in New York and Beijing.

"As we enter this important next phase in our Company's growth and expansion, we also plan to accelerate our communications efforts with key investment audiences in the U.S. and China," said Weibing Lu, Chairman and Chief Executive Officer of Skystar. "We selected TPG as our partners in investor relations given their strong relationships on Wall Street and expertise representing China-based companies in the U.S. markets."

Brandi Piacente, President of TPG, stated, "We are delighted to represent Skystar by introducing the Company's track record of strong revenue and earnings growth, highly competitive products, and proven management team to key investment audiences. We look forward to further developing Skystar's public company profile and making new connections in the financial community on behalf of the Company."

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products, with over 40 additional products in the developmental stage. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit [ http://www.skystarbio-pharmaceutical.com ].

To be added to the Company's email distribution for future news releases, please send your request to [ kristen@tpg-ir.com ].

Forward-looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.